ALLO-647

Phase 2

Allogene Therapeutics, Inc. (ALLO)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

ALLOPhase 2$690M

Cyclophosphamide Phase 2 Est. Readout

ALLO-647• Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma250

Q3 2027~QConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

View Full Landscape

Drug Information

Target Indication

Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

Clinical Trial

NCT04416984

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ALLO

Allogene Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts